SCHEMBL20017320

SCHEMBL20017320

N/C(=N\N=C(/N)c1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.54
LMNA P02545 5/20 0.52
MAPT P10636 5/20 0.44
HSD17B10 Q99714 5/20 0.44
CYP3A4 P08684 5/20 0.44
HIF1A Q16665 5/20 0.44
CA12 O43570 4/20 0.44
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA9 Q16790 4/20 0.44
ALOX15 P16050 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
CA3 P07451 3/20 0.44
CA14 Q9ULX7 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
TYR P14679 2/20 0.44
CA4 P22748 2/20 0.44
CA5A P35218 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22043774 0.89 NOS3 (0.48) KDM1ALMNAMAPTHSD17B10CYP3A4
SCHEMBL22815269 0.82 KDM1A (0.48) KDM1ALMNAMAPTHSD17B10CYP3A4
SCHEMBL12873713 0.81 KDM1A (0.76) KDM1ALMNAMAPTHSD17B10CYP3A4
SCHEMBL771386 0.81 KDM1A (0.76) KDM1ALMNAMAPTHSD17B10CYP3A4
SCHEMBL1187298 0.81 KDM1A (0.76) KDM1ALMNAMAPTHSD17B10CYP3A4
SCHEMBL14393378 0.79 KDM1A (0.50) KDM1ALMNAMAPTHSD17B10CYP3A4
SCHEMBL21553910 0.78 PLAU (0.52) LMNAMAPTHSD17B10CYP3A4HIF1A
SCHEMBL7717290 0.75 LMNA (0.39) KDM1ALMNAHSD17B10HIF1AMEN1
SCHEMBL18938347 0.74 KMT2A (0.61) MAPTHSD17B10CYP3A4HIF1AMEN1
SCHEMBL9628010 0.74 KDM1A (0.46) KDM1ALMNAMAPTHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4245744-A2 CHEMICALLY CLEAVABLE GROUP Tagworks Pharmaceuticals B.V. (NL) 2023-09-20 EP disclosed
US-20210162060-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2021-06-03 US disclosed
US-10967069-B2 Bio-orthogonal drug activation TAGWORKS PHARMACEUTICALS B.V. (NL) 2021-04-06 US disclosed
US-10927139-B2 Chemically cleavable group TAGWORKS PHARMACEUTICALS B.V. (NL) 2021-02-23 US disclosed
US-20190336612-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2019-11-07 US disclosed
US-9931408-B2 Bio-orthogonal drug activation KONINKLIJKE PHILIPS N.V. (NL) 2018-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10967069-B2 Bio-orthogonal drug activation JMJD7, KIT, PAICS KDM1A 1573/4885LMNA 4539/4885MAPT 2466/4885
US-20210162060-A1 BIO-ORTHOGONAL DRUG ACTIVATION JMJD7, KIT, PAICS KDM1A 1573/4885LMNA 4539/4885MAPT 2466/4885
US-10927139-B2 Chemically cleavable group SQLE, CTRL, ENO1 KDM1A 4425/4885LMNA 1188/4885MAPT 2604/4885
US-20190336612-A1 BIO-ORTHOGONAL DRUG ACTIVATION JMJD7, KIT, PAICS KDM1A 1573/4885LMNA 4539/4885MAPT 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.